Enlonstobart
drugOn this page
Also known as SG-001Sg001
Summary
Enlonstobart (CHEMBL5315040) is a phase-3 clinical-stage antibody targeting PDCD1; indicated across 6 conditions including neoplasm and breast neoplasm.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Antibody
- Targets: 1 (PDCD1)
- Indications: 6 conditions
- Clinical trials: 19
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5315040 |
| Name | Enlonstobart |
| Type | Antibody |
| Max phase | 3 |
Also known as: Enlonstobart, SG-001, Sg001, ENLONSTOBART
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| PDCD1 | programmed cell death 1 (CD279) | Binding | 0% | Q15116 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): PDCD1.
Top Reactome pathways
3 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Co-inhibition by PD-1 | 1 | PDCD1 |
| Potential therapeutics for SARS | 1 | PDCD1 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | 1 | PDCD1 |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| B cell apoptotic process | 1 |
| adaptive immune response | 1 |
| negative regulation of tolerance induction | 1 |
| negative regulation of T cell mediated immune response to tumor cell | 1 |
| negative regulation of B cell apoptotic process | 1 |
| apoptotic process | 1 |
| humoral immune response | 1 |
| negative regulation of inflammatory response | 1 |
| regulation of immune response | 1 |
| negative regulation of immune response | 1 |
| negative regulation of T cell receptor signaling pathway | 1 |
| negative regulation of T cell activation | 1 |
| positive regulation of T cell apoptotic process | 1 |
| regulatory T cell apoptotic process | 1 |
| immune system process | 1 |
Indications & clinical
Indications
6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 2 | MONDO:0005070 | EFO:0000616 |
| breast neoplasm | 2 | MONDO:0021100 | MONDO:0007254 |
| lymphoma | 1 | MONDO:0005062 | EFO:0000574 |
| mesothelioma | 1 | MONDO:0005065 | EFO:0000588 |
| non-small cell lung carcinoma | 1 | MONDO:0005233 | EFO:0003060 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 19.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 10 |
| PHASE1/PHASE2 | 5 |
| PHASE2/PHASE3 | 2 |
| PHASE3 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05715840 | PHASE3 | NOT_YET_RECRUITING | Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1) |
| NCT07251062 | PHASE2/PHASE3 | NOT_YET_RECRUITING | A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. |
| NCT07332533 | PHASE2/PHASE3 | NOT_YET_RECRUITING | A Study of KN026-based Combination Therapy in HER2-positive Gastric Cancer |
| NCT06132217 | PHASE1/PHASE2 | NOT_YET_RECRUITING | A Study of Simmitinib Plus SG001 in Advanced Solid Tumors |
| NCT06136988 | PHASE1/PHASE2 | NOT_YET_RECRUITING | A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. |
| NCT06682611 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors. |
| NCT06981858 | PHASE2 | NOT_YET_RECRUITING | A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer |
| NCT06989671 | PHASE2 | NOT_YET_RECRUITING | SYS6002 Plus JMT101 and Enlonstobart Injection in Participants With HNSCC |
| NCT06998771 | PHASE2 | NOT_YET_RECRUITING | JSKN003 Combined Treatment of HER2-positive Gastric Cancer |
| NCT07183865 | PHASE2 | RECRUITING | Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY-R) |
| NCT07254585 | PHASE2 | RECRUITING | SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma |
| NCT07282509 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer |
| NCT04886700 | PHASE2 | UNKNOWN | Study of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical Cancer |
| NCT04983550 | PHASE2 | UNKNOWN | Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC |
| NCT05009953 | PHASE2 | TERMINATED | Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer |
| NCT05068141 | PHASE2 | UNKNOWN | A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC) |
| NCT05508659 | PHASE1/PHASE2 | UNKNOWN | A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors |
| NCT06089330 | PHASE2 | UNKNOWN | A Study of JMT101 in Patients With Metastatic Colorectal Cancer |
| NCT03852823 | PHASE1 | UNKNOWN | Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
4 molecules share ≥1 primary target. Top 4 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| PYRVINIUM | ChEMBL | Phase 4 (approved) | PDCD1 |
| RIFABUTIN | ChEMBL | Phase 4 (approved) | PDCD1 |
| Gefitinib | PubChem | Approved | PDCD1 |
| Pomalidomide | PubChem | Approved | PDCD1 |
Related Atlas pages
- Genes: PDCD1
- Drugs: Pyrvinium, Rifabutin, Gefitinib, Pomalidomide